Market Access NICE contribution to the cost per QALY threshold debate? Leela Barham sets out some wider context to the latest blog from NICE on the cost-effectiveness threshold used by the agency and highlights the opportunity for stakeholders to build their c
R&D Life Sciences Industry Report - Biologics and Generics The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.
News Medicare price negotiations 'will continue under Trump' President Trump will continue Medicare drug pricing negotiation but intends to look for improvements to the scheme according to CMS.
News Vaccines dominate questioning at RFK Jr's first hearing Robert F Kennedy Jr's first confirmation hearing was a fractious affair, marked by tough questions about his prior anti-vaccine stance.
News Lyfegen partners EVERSANA on pricing, access resource Lyfegen and EVERSANA have joined forces to help pharma companies navigate an increasingly complex global drug pricing and access environment.
News Trump pulls Biden policies on health insurance, drug pricing President Trump has started dismantling health legislation introduced under the Biden administration on day one of his new term.
News Remepy's hybrid Parkinson's therapy poised for phase 3 Remepy's Hybridopa therapy for Parkinson's, which combines an app with levodopa therapy, has shown efficacy in a phase 2 pilot study.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.